Fintel reports that on October 2, 2023, Cantor Fitzgerald maintained coverage of LifeMD (NASDAQ:LFMD) with a Overweight recommendation.
Analyst Price Forecast Suggests 22.40% Upside
As of August 31, 2023, the average one-year price target for LifeMD is 7.65. The forecasts range from a low of 7.07 to a high of $9.45. The average price target represents an increase of 22.40% from its latest reported closing price of 6.25.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for LifeMD is 168MM, an increase of 30.24%. The projected annual non-GAAP EPS is -0.01.
What is the Fund Sentiment?
There are 67 funds or institutions reporting positions in LifeMD. This is an increase of 7 owner(s) or 11.67% in the last quarter. Average portfolio weight of all funds dedicated to LFMD is 0.04%, an increase of 57.84%. Total shares owned by institutions decreased in the last three months by 13.03% to 6,642K shares. 
The put/call ratio of LFMD is 0.23, indicating a bullish outlook.
What are Other Shareholders Doing?
Royce & Associates holds 1,020K shares representing 2.83% ownership of the company. In it's prior filing, the firm reported owning 1,070K shares, representing a decrease of 4.90%. The firm increased its portfolio allocation in LFMD by 136.60% over the last quarter.
ROFCX - Royce Opportunity Fund Consultant Class holds 646K shares representing 1.79% ownership of the company. In it's prior filing, the firm reported owning 678K shares, representing a decrease of 4.95%. The firm increased its portfolio allocation in LFMD by 139.44% over the last quarter.
EAM Investors holds 477K shares representing 1.32% ownership of the company.
B. Riley Financial holds 464K shares representing 1.29% ownership of the company. In it's prior filing, the firm reported owning 922K shares, representing a decrease of 98.79%. The firm increased its portfolio allocation in LFMD by 16.83% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 431K shares representing 1.20% ownership of the company. No change in the last quarter.
LifeMD Background Information
(This description is provided by the company.)
LifeMD, Inc. (formerly Conversion Labs) is a leading telehealth company that is transforming the healthcare landscape with direct-to-patient product and service offerings. LifeMD's telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate, prescription medications and over-the-counter products delivered directly to the patient's home.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
